Autopsy report · NCT02684084

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study revised significantly. New trial to be launched.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 1 year 1 month before it stopped.
5 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 4
Sponsor: North Toronto Eye Care Laser and Eye Specialists
Sponsor type: University, hospital or other
Conditions: Diabetic Macular Edema
Interventions: Ozurdex; Lucentis
Participants: 5
Sites: 2
Countries: Canada

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.